Court Rejects Merck Challenge to Medicare Drug Price Negotiation Program
Court rejects Merck's lawsuit against Medicare drug price negotiations. Penalties for noncompliance include steep excise taxes.
A court said Merck has to follow Medicare's new rules where the government helps negotiate lower prices for medicines. This means the company faces big tax penalties if it doesn't cooperate with the price-negotiation program.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.